ARCT - Arcturus Therapeutics Holdings Inc.
Hsbc Holdings PLC acquired a new position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 56,895 shares of the biotechnology company's stock, valued at approximately $394,000. Hsbc Holdings PLC
BlackRock Inc. bought a new position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) in the undefined quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 2,614,012 shares of the biotechnology company's stock, valued at approximately $17,566,000. BlackRock Inc. owned 9.20% of Arcturus Therapeutics
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will participate in the following investor conferences: Wells Fargo 21st Annual Healthcare Conference (Boston) | Fireside Chat September 8, 2026 (2:15 p.m. ET) Citi's 2026 Biopharma Back to School Conference (New York) | Fireside Chat September 9.
After reaching an important support level, Arcturus Therapeutics Holdings Inc. (ARCT) could be a good stock pick from a technical perspective. ARCT recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
Arcturus Therapeutics NASDAQ: ARCT is positioning its mRNA platform around two rare-disease programs targeting cystic fibrosis and ornithine transcarbamylase deficiency, while its vaccine business is intended to help support therapeutic development, President and CEO Joseph Payne said during a Canaccord discussion.
Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2026 Earnings Call Transcript
Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.84 per share versus the Zacks Consensus Estimate of a loss of $1.07. This compares to a loss of $0.34 per share a year ago.
Arcturus Therapeutics NASDAQ: ARCT reported progress across its rare-disease pipeline during the second quarter of 2026, completed enrollment and dosing in its Phase II ornithine transcarbamylase deficiency study, and regained global rights to its KOSTAIVE COVID-19 vaccine and self-amplifying mRNA platform following the end of its collaboration with CSL Seqirus.
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced its financial results for the quarter ended June 30, 2026, and provided corporate updates. “We are encouraged by the continued progress of our ARCT-032 Phase 2 cystic fibrosis study, with active screening and ongoing enrollment across sites in the United States,.
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that it will release its financial results for the quarter ended June 30, 2026, after the market close on Thursday, Aug 6th and will also host a conference call and webcast at 4:30 pm Eastern Time on Aug 6, 2026. Arcturus Therapeutics Second Quarter 2026 Earnings.
Zenas BioPharma (NASDAQ: ZBIO - Get Free Report) and Arcturus Therapeutics (NASDAQ: ARCT - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, dividends, earnings, institutional ownership and profitability. Earnings and Valuation This table compares Zenas
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the eleven analysts that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, six have issued a buy recommendation and one has
Amova Asset Management Americas Inc. grew its holdings in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) by 12.9% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,288,935 shares of the biotechnology company's stock after purchasing an additional 262,347
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will present at the following investor conference in Boston, Massachusetts: Canaccord Genuity 46th Annual Growth Conference (Fireside Chat) Tuesday, August 11, 2026 (12:00 p.m. ET) Webcast link can be found under Investor Relations/Events section.
Arcturus has dropped off enough to make it a net-cash stock - a stock trading for less its current asset value with all liabilities subtracted. A peer group of similar issues that I have rated here on Seeking Alpha has strongly outperformed the S&P 500 even through one of the strongest bull markets in history. This and the combination of a revenue generating asset portfolio and promising pipeline make Arcturus a compelling opportunity.
Arcturus Therapeutics (ARCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is collaborating with Thermo Fisher Scientific Inc. (NYSE:TMO) to support the Phase 3 development and potential commercialization of ARCT-032, the company's investigational messenger RNA therapy for cystic fibrosis.
Arcturus Therapeutics Holdings Inc. (âArcturusâ, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (“Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced a strategic collaboration with Thermo Fisher Scientific, the world leader in serving science, to help support the Phase 3 development and potential commercialization of ARCT-032, Arcturus' investigational mRNA therapy for Cystic Fibrosis. The collaboration will leverage Thermo.
The world uses a lot of copper, but thanks to the energy transition and data centers, it'll need a lot more. Between now and 2050, we'll have to produce more copper than has been mined throughout all of human history, according to one study.